Overview Of Value Stocks In The Consumer Defensive Sector

What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

What are Value Stocks?

A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company’s future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

Below is a list of notable value stocks in the consumer defensive sector:

  1. RLX Technology (NYSE:RLX) – P/E: 4.21
  2. Pilgrims Pride (NASDAQ:PPC) – P/E: 8.93
  3. China Online Education Gr (NYSE:COE) – P/E: 3.39
  4. Industrias Bachoco SAB (NYSE:IBA) – P/E: 7.33
  5. DAVIDsTEA (NASDAQ:DTEA) – P/E: 0.67

This quarter, RLX Technology experienced a decrease in earnings per share, which was $0.06 in Q4 and is now $0.04. Pilgrims Pride’s earnings per share for Q2 sits at $1.54, whereas in Q1, they were at 1.18. This quarter, China Online Education Gr experienced an increase in earnings per share, which was $-0.94 in Q1 and is now $-0.67. Industrias Bachoco SAB’s earnings per share for Q2 sits at $2.94, whereas in Q1, they were at 2.17. The company’s most recent dividend yield sits at 2.28%, which has increased by 0.23% from 2.05% last quarter.

DAVIDsTEA saw a decrease in earnings per share from 0.06 in Q4 to $-0.04 now.

The Significance: A value stock may need some time to rebound from its undervalued position. The risk of investing in a value stock is that this emergence may never materialize.

Total
0
Shares
Related Posts
Read More

Zai Lab To Present Analysis Of The Impact Of Timing For ZEJULA Maintenance Treatment In Newly Diagnosed Advanced Ovarian Cancer At The 2022 International Gynecologic Cancer Society Meeting September 29 – October 1, 2022

SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)))), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will

ZLAB